Abstract 2281
Background
TM is a useful tool that improves access to medical care for rural residents. However, factors that correlate with a positive TM experience are not well known. The study aims to determine TM experience in cancer patients and physicians, and to explore clinical and socio-economic factors (CSF) that are associated with a positive TM experience in patients.
Methods
In this cross-sectional study cancer patients on active treatment and physicians in the province of Saskatchewan, Canada completed a paper-based comprised of 32 items or an electronic survey of 18 items, respectively. Six point likert score was used. Logistic regression analysis was done to assess correlation between self-reported CSF and a positive TM experience. We present here preliminary results.
Results
Overall 25 physicians and 165 patients responded to the survey over a period of three months. Among physicians 69% were in practice for ≥10 yrs with M:F of 1.7:1. 94% were confident in their TM assessment, 58% felt that TM improve clinical efficiency, and 74% felt that doctor-patient rapport was unimpaired with TM. Of 165 patients with median age of 67 years (IQR 59-75) and M:F of 1.06:1, 60% were ≥65 yrs, 70% were married, and 82% had a dependent family member. 94% were born in Canada, 77% were Caucasian, 29% were working and 35% had annual income of < 40K. 67% had solid tumor, 46% reported having a curable cancer, 31% had surgery, 27% had radiation, and 62% had chemotherapy. 61% used TM first time. 90% felt that their needs were met, 91% felt that TM improved their quality of care, and 91% had a good experience. Overall, 83% patients vs. 45% physicians preferred TM to in-person clinic visit (P = 0.005). Only univariate analysis only age ≥65 was strongly associated with a positive TM experience, odd ratio 4.1 (1.2-13.8), p = 0.02. No other CSF including marital status, income, working status, dependent family member, and cancer type were significantly correlated with a positive TM experience.
Conclusions
This study supports a higher rate of positive TM experience in cancer patients and physicians. However, high preference of TM was noted among patient compared with physicians. Among various variables examined only older age was associated with a positive TM experience.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shahid Ahmed.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5141 - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)
Presenter: Stephanie Yaung
Session: Poster Display session 1
Resources:
Abstract
5189 - Association between serum HGF levels and neutrophil counts in small cell lung cancer and their impact on survival
Presenter: Laura Moliner
Session: Poster Display session 1
Resources:
Abstract
3539 - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC.
Presenter: Clelia Tiziana Storlazzi
Session: Poster Display session 1
Resources:
Abstract
3438 - High-biologically effective dose radiotherapy improve the survival of small cell lung cancer patients with brain metastases: a propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster Display session 1
Resources:
Abstract
3232 - Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract
3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
Presenter: Carminia Maria Della Corte
Session: Poster Display session 1
Resources:
Abstract
3745 - Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer
Presenter: Yamei Chen
Session: Poster Display session 1
Resources:
Abstract
5049 - CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer
Presenter: Alejandro Navarro Mendivil
Session: Poster Display session 1
Resources:
Abstract
5997 - Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC): The PAVE study, a Hellenic Cooperative Oncology Group Study
Presenter: Helena Linardou
Session: Poster Display session 1
Resources:
Abstract
4502 - Tobacco use in lung cáncer (LC) patients (p) in Spain
Presenter: Enric Carcereny Costa
Session: Poster Display session 1
Resources:
Abstract